HALOZYME THERAPEUTICS, INC. - Common Stock (HALO)

Q2 2022 13F Holders as of 30 Jun 2022

Type / Class
Equity / Common Stock
Shares outstanding
123,650,000
Total 13F shares
125,312,165
Share change
+1,133,006
Total reported value
$5,514,781,837
Put/Call ratio
34%
Price per share
$44.00
Number of holders
353
Value change
+$52,891,963
Number of buys
199
Number of sells
128

Institutional Holders of HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) as of Q2 2022

As of 30 Jun 2022, HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) was held by 353 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 125,312,165 shares. The largest 10 holders included BlackRock Inc., VANGUARD GROUP INC, Artisan Partners Limited Partnership, STATE STREET CORP, Invesco Ltd., WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC, SNYDER CAPITAL MANAGEMENT L P, JPMORGAN CHASE & CO, MACQUARIE GROUP LTD, and GEODE CAPITAL MANAGEMENT, LLC. This page lists 355 institutional shareholders reporting positions in this security for the Q2 2022 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.